Status:

RECRUITING

TorasEmide Induced Effect on QoL and Clinical parameterS in paTients With chronIc heArt Failure Receiving Eplerenone.

Lead Sponsor:

Elpen Pharmaceutical Co. Inc.

Conditions:

Chronic Heart Failure

Eligibility:

All Genders

18-90 years

Brief Summary

Heart failure (HF) is a multisystemic disorder characterized by marked disturbances in the physiology of the circulatory system and a multitude of structural and functional changes in the myocardium t...

Detailed Description

Eplerenone is more specific in blocking aldosterone and therefore causes less gynecomastia. Eplerenone is indicated in addition to standard therapy including β-blockers to reduce the risk of cardiovas...

Eligibility Criteria

Inclusion

  • Adult patients (≥ 18 years) with a diagnosis of Chronic Heart Failure (CHF)
  • Patients who are on treatment with torasemide added on to eplerenone treatment, from 1 to 7 days before study initiation.
  • Patients who are able to provide informed consent and follow study procedures and requirements.

Exclusion

  • Patients with hypersensitivity to the active substance of torasemide, sulfonylureas or to any of the excipients mentioned in torasemide SmPC.
  • Patients with renal failure with anuria.
  • Patients in hepatic coma, or pro-coma.
  • Patients with intolerance to galactose, complete lactase deficiency or glucose-galactose malabsorption.
  • Patients with hypotension.
  • Patients with cardiac arrhythmias.
  • Patients with parallel treatment with aminoglycosides or cephalosporins.
  • Patients with kidney dysfunction due to drugs that cause kidney damage.
  • The addition during the study of other drugs with a direct effect on diuresis (such as other diuretics or SGLT2 inhibitors).
  • Patients who are unable to comply with the study protocol procedures and requirements.

Key Trial Info

Start Date :

March 6 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2025

Estimated Enrollment :

210 Patients enrolled

Trial Details

Trial ID

NCT06117722

Start Date

March 6 2024

End Date

December 31 2025

Last Update

July 22 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

ATTIKON University Hospital

Athens, Attica, Greece, 12462